Miller W J, Branda R F, Flynn P J, Howe R B, Ramsay N K, Condie R M, Jacob H S
Br J Haematol. 1983 Sep;55(1):17-25. doi: 10.1111/j.1365-2141.1983.tb01220.x.
Nineteen patients with severe aplastic anaemia were treated with antithymocyte globulin. Ten patients obtained remissions (transfusion independent, at least 45000 platelets and 2000 PMN/mm3) within 2-3 months and continue in remission 5-35 months after antithymocyte globulin. Ages of responders ranged from 17 to 71. Complications of antithymocyte globulin included arthralgias, rash, serum sickness, angioedema and fever. Two patients died during, two shortly after, and one 10 months after therapy. One patient with a previous remission following antithymocyte globulin relapsed and achieved a second remission with retreatment. Previous androgen therapy did not affect outcome since two of four patients with and eight of 15 patients without previous androgen therapy achieved remission with ATG. Treatment with antithymocyte globulin is a promising alternative to bone marrow transplantation in the treatment of severe aplastic anaemia.
19例重型再生障碍性贫血患者接受了抗胸腺细胞球蛋白治疗。其中10例患者在2至3个月内获得缓解（无需输血，血小板至少45000/μl，中性粒细胞2000/μl），并在接受抗胸腺细胞球蛋白治疗后5至35个月持续缓解。缓解者年龄在17至71岁之间。抗胸腺细胞球蛋白的并发症包括关节痛、皮疹、血清病、血管性水肿和发热。2例患者在治疗期间死亡，2例在治疗后不久死亡，1例在治疗后10个月死亡。1例曾在接受抗胸腺细胞球蛋白治疗后缓解的患者复发，再次治疗后获得第二次缓解。既往雄激素治疗不影响治疗结果，因为4例接受过雄激素治疗的患者中有2例、15例未接受过雄激素治疗的患者中有8例接受抗胸腺细胞球蛋白治疗后获得缓解。在重型再生障碍性贫血的治疗中，抗胸腺细胞球蛋白治疗是骨髓移植的一种有前景的替代方法。
